PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator specializing in haematology and oncology, proudly announces the launch of BESREMi®️ (ropeginterferon alfa-2b) in Singapore. This marks a significant milestone as Singapore becomes the first market in Southeast Asia to offer this groundbreaking treatment for Polycythaemia Vera (PV). The launch is timely, coinciding with MPN (Myeloproliferative Neoplasms) Awareness Day on 12 September, underscoring PharmaEssentia's commitment to addressing unmet medical needs and enhancing patient outcomes.

Advancing PV Treatment and Awareness

Polycythaemia Vera (PV) is a rare blood cancer caused by the abnormal and uncontrolled production of blood cells in the bone marrow. With approximately 500 PV patients in Singapore and an estimated 5,000 across Southeast Asia, awareness of the disease remains low, complicating effective disease management. MPN Awareness Day is pivotal in educating the public and healthcare professionals about PV, emphasizing the importance of early detection, diagnosis, and timely treatment.

Dr. Peggy Loh, General Manager of PharmaEssentia Singapore, commented:
"Today represents a key milestone in PV treatment in Singapore. BESREMi®️ offers an innovative solution that directly targets the root cause of the disease, enabling long-term control and reducing the risk of progression and thrombosis. It is the first therapy approved by the HSA for adults with PV, regardless of their treatment history. This launch is especially timely for patients seeking advanced treatment options to achieve their desired healthcare outcomes. We look forward to collaborating with Singapore's healthcare community to foster comprehensive treatment approaches."

BESREMi®: A Major Advancement in PV Care

BESREMi®️ was first approved by the U.S. FDA in 2021 as the only interferon therapy for adults with PV, representing a transformative shift in disease management. Developed through rigorous research and clinical trials, BESREMi®️ is now available in key global markets, including the United States, Europe, the United Kingdom, Israel, South Korea, Japan, Taiwan, China, Macau, and Malaysia. Unlike traditional therapies that primarily manage symptoms, BESREMi®️ addresses the underlying cause of PV, offering comprehensive disease control and improving long-term outcomes and quality of life for both patients and caregivers.

Dr. Ko-Chung Lin, Founder and CEO of PharmaEssentia, noted:
"Introducing BESREMi®️ in Singapore is a pivotal moment for us. Our commitment to advancing biomedical research, combined with Singapore's reputation as a leading medical hub, allows us to make a significant impact on this underserved condition. We are proud to play a role in improving care for PV patients across the region."

The Importance of Early Detection

Dr. Ng Chin Hin, Senior Consultant at the Centre for Clinical Haematology, explained the critical importance of early diagnosis:
"Polycythaemia Vera is a rare disorder caused by the JAK2 genetic mutation. Its symptoms—such as headaches, fatigue, and blurred vision—are often non-specific and can easily be mistaken for other conditions like migraines or stress. Early diagnosis is essential as untreated PV is associated with a higher risk of stroke, heart attack, and other life-threatening complications due to blood clots."

Dr. Dawn Mya Hae Tha, Senior Consultant at Parkway Cancer Centre, added:
"Routine health screenings, including a full blood count, are vital for early detection of abnormalities in blood cell counts. Many patients come to us only when complications have advanced. Early intervention can make a significant difference in patient outcomes."

Supporting MPN Awareness

As MPN Awareness Day approaches on 12 September 2024, PharmaEssentia encourages PV patients, caregivers, and healthcare providers to come together in raising awareness about PV. By sharing experiences, they can increase understanding of this rare condition, build greater support, and promote early detection to improve the quality of life for those affected.